DK1344524T3 - Refluksinhibitorer - Google Patents

Refluksinhibitorer

Info

Publication number
DK1344524T3
DK1344524T3 DK03013667T DK03013667T DK1344524T3 DK 1344524 T3 DK1344524 T3 DK 1344524T3 DK 03013667 T DK03013667 T DK 03013667T DK 03013667 T DK03013667 T DK 03013667T DK 1344524 T3 DK1344524 T3 DK 1344524T3
Authority
DK
Denmark
Prior art keywords
reflux inhibitors
reflux
inhibitors
Prior art date
Application number
DK03013667T
Other languages
English (en)
Inventor
Anders Lehmann
Paul L R Andrews
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20403936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1344524(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1344524T3 publication Critical patent/DK1344524T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406Neurotransmitters
    • G01N33/9426GABA, i.e. gamma-amino-butyrate
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK03013667T 1996-09-18 1997-09-15 Refluksinhibitorer DK1344524T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9603408A SE9603408D0 (sv) 1996-09-18 1996-09-18 Medical use
EP97942346A EP0936906B1 (en) 1996-09-18 1997-09-15 Reflux inhibitors

Publications (1)

Publication Number Publication Date
DK1344524T3 true DK1344524T3 (da) 2006-10-30

Family

ID=20403936

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97942346T DK0936906T3 (da) 1996-09-18 1997-09-15 Refluxhæmmere
DK03013667T DK1344524T3 (da) 1996-09-18 1997-09-15 Refluksinhibitorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK97942346T DK0936906T3 (da) 1996-09-18 1997-09-15 Refluxhæmmere

Country Status (35)

Country Link
US (2) US6117908A (da)
EP (2) EP1344524B1 (da)
JP (1) JP4098832B2 (da)
KR (2) KR100568659B1 (da)
CN (1) CN1117560C (da)
AR (1) AR007747A1 (da)
AT (2) ATE249212T1 (da)
AU (1) AU714370B2 (da)
BR (1) BR9711400A (da)
CA (1) CA2265615C (da)
CZ (1) CZ299997B6 (da)
DE (2) DE69736445T2 (da)
DK (2) DK0936906T3 (da)
EE (1) EE03952B1 (da)
ES (2) ES2268227T3 (da)
HK (2) HK1022100A1 (da)
HU (1) HU224968B1 (da)
ID (1) ID19621A (da)
IL (1) IL128961A (da)
IS (2) IS2329B (da)
MY (1) MY122020A (da)
NO (1) NO326837B1 (da)
NZ (2) NZ334495A (da)
PL (1) PL190028B1 (da)
PT (2) PT936906E (da)
RU (1) RU2199316C2 (da)
SA (1) SA97180522B1 (da)
SE (1) SE9603408D0 (da)
SI (2) SI1344524T1 (da)
SK (1) SK285744B6 (da)
TR (1) TR199900591T2 (da)
TW (1) TW548104B (da)
UA (1) UA61081C2 (da)
WO (1) WO1998011885A1 (da)
ZA (1) ZA977969B (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0934061T6 (da) 1996-07-24 2015-01-26 Warner Lambert Co Isobutylgaba og dets derivater til behandling af smerte
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
TWI256314B (en) * 2000-02-09 2006-06-11 Mitsubishi Pharma Corp Preventive-therapeutical medicament for gastroesophageal reflux disease
WO2002096404A1 (en) * 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
SE0102055D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Compounds
SE0102058D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts II
AR033779A1 (es) * 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
SE0102057D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts I
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
SE0201939D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination
SE0201940D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
JP2006513257A (ja) * 2002-12-13 2006-04-20 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 線維筋痛症および他の障害を処置するためのプレガバリン誘導体
KR101140559B1 (ko) * 2003-08-20 2012-07-05 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
KR20060120612A (ko) * 2003-09-12 2006-11-27 얀센 파마슈티카 엔.브이. 키메라 gabab 수용체
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050220863A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US7566738B2 (en) * 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006071186A1 (en) * 2004-12-27 2006-07-06 Astrazeneca Ab Use of gabab receptor agonists
JP2009521426A (ja) * 2005-12-23 2009-06-04 アストラゼネカ・アクチエボラーグ ヘテロ環gaba−bモジュレーター
BRPI0620373A2 (pt) * 2005-12-23 2011-11-08 Astrazeneca Ab composto e sais farmaceuticamente e farmacologicamente aceitáveis dos mesmos, e enantiÈmeros do composto e sais dos mesmos, uso dos mesmos, opcionalmente em combinação com um agonista do receptor de gabab,e , composição farmaceutica
KR20080091452A (ko) * 2005-12-23 2008-10-13 아스트라제네카 아베 위장 장애의 치료를 위한 이미다졸 유도체
KR20080090449A (ko) * 2005-12-23 2008-10-08 아스트라제네카 아베 Gerd 및 ibs의 치료를 위한 피라졸
AU2006327317B2 (en) 2005-12-23 2010-11-25 Astrazeneca Ab GABA-B receptor modulators
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
ZA200904573B (en) 2006-12-22 2010-09-29 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
JP2010515754A (ja) * 2007-01-11 2010-05-13 ゼノポート,インコーポレイティド R−バクロフェンのプロドラッグの徐放性経口剤形及び治療方法
CN101679444A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 具有正变构gabab受体调节剂作用的黄嘌呤化合物
TW200908957A (en) * 2007-06-15 2009-03-01 Xenoport Inc Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
WO2009014491A1 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab The use of (3-amino-2-fluoropropyl) phosphinic acid for treatment of nerd
WO2009061934A1 (en) * 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
CA2710538A1 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
US8993639B2 (en) * 2008-03-20 2015-03-31 Burt Shulman Compound and method for treatment of gastroesophageal reflux
US8299291B2 (en) * 2008-08-07 2012-10-30 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
CN102341099A (zh) 2009-03-03 2012-02-01 什诺波特有限公司 R-巴氯芬前药的持续释放口服剂型
JP2012524065A (ja) * 2009-04-17 2012-10-11 ゼノポート,インコーポレーテッド GABAB受容体リガンドとしてのγ−アミノ酪酸誘導体
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
WO2013023155A1 (en) 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
EP2854774A4 (en) 2012-06-01 2015-11-18 Lynn Health Science Inst Inc METHODS OF TREATING INSOMNIA
TW202412754A (zh) * 2022-06-07 2024-04-01 瑞士商意梭凱普公司 應用於食道黏膜的包含逆流抑制劑的藥物傳遞系統

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594424B2 (en) * 1986-01-03 1990-03-08 University Of Melbourne, The Gastro-oesophageal reflux composition
NO882881L (no) * 1988-06-29 1990-01-02 Trond Nilsen Anordning for lengdekorrugering av metallplater.
WO1990009096A2 (en) * 1989-02-03 1990-08-23 Cambridge Neuroscience Research, Inc. Method of screening and classifying compounds
GB9117716D0 (en) * 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
ES2174897T3 (es) * 1992-01-22 2002-11-16 Glaxo Group Ltd Uso medico de agonistas de beta-adrenoceptores atipicos.
GB9408064D0 (en) * 1994-04-22 1994-06-15 Merck Sharp & Dohme Nucleic acids
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions

Also Published As

Publication number Publication date
JP4098832B2 (ja) 2008-06-11
ATE249212T1 (de) 2003-09-15
TR199900591T2 (xx) 1999-07-21
KR100568659B1 (ko) 2006-04-07
DE69736445T2 (de) 2007-03-15
IL128961A0 (en) 2000-02-17
NZ334495A (en) 2000-09-29
NO326837B1 (no) 2009-02-23
BR9711400A (pt) 1999-08-17
KR100553294B1 (ko) 2006-02-22
ATE334700T1 (de) 2006-08-15
EP1344524B1 (en) 2006-08-02
NO991287L (no) 1999-03-17
AR007747A1 (es) 1999-11-10
IS5001A (is) 1999-03-15
PT936906E (pt) 2003-12-31
NO991287D0 (no) 1999-03-17
CN1237105A (zh) 1999-12-01
ES2268227T3 (es) 2007-03-16
US6117908A (en) 2000-09-12
PT1344524E (pt) 2006-11-30
ES2206749T3 (es) 2004-05-16
NZ504244A (en) 2000-09-29
CA2265615C (en) 2007-01-30
ID19621A (id) 1998-07-23
DE69724809T2 (de) 2004-07-15
AU4406497A (en) 1998-04-14
WO1998011885A1 (en) 1998-03-26
DE69736445D1 (de) 2006-09-14
KR20050101237A (ko) 2005-10-20
MY122020A (en) 2006-03-31
EP0936906B1 (en) 2003-09-10
ZA977969B (en) 1998-03-18
HU224968B1 (en) 2006-04-28
HUP9903825A2 (hu) 2001-05-28
PL190028B1 (pl) 2005-10-31
SI0936906T1 (en) 2004-02-29
US6664069B1 (en) 2003-12-16
SE9603408D0 (sv) 1996-09-18
HUP9903825A3 (en) 2001-06-28
SK30599A3 (en) 2000-01-18
EE9900095A (et) 1999-10-15
DK0936906T3 (da) 2003-11-24
SA97180522B1 (ar) 2006-04-04
CA2265615A1 (en) 1998-03-26
HK1057004A1 (en) 2004-03-12
SI1344524T1 (sl) 2006-12-31
AU714370B2 (en) 1999-12-23
CZ93099A3 (cs) 1999-09-15
PL332497A1 (en) 1999-09-13
TW548104B (en) 2003-08-21
RU2199316C2 (ru) 2003-02-27
UA61081C2 (uk) 2003-11-17
HK1022100A1 (en) 2000-07-28
EP1344524A1 (en) 2003-09-17
EP0936906A1 (en) 1999-08-25
KR20000036185A (ko) 2000-06-26
IS2538B (is) 2009-09-15
DE69724809D1 (de) 2003-10-16
IS8623A (is) 2007-03-19
CZ299997B6 (cs) 2009-01-14
IL128961A (en) 2004-08-31
CN1117560C (zh) 2003-08-13
JP2001501604A (ja) 2001-02-06
EE03952B1 (et) 2003-02-17
SK285744B6 (sk) 2007-07-06
IS2329B (is) 2008-01-15

Similar Documents

Publication Publication Date Title
DE69736445D1 (de) Refluxinhibitoren
FI963597A0 (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
FI972160A (fi) Matriisimetalloproteaasi-inhibiittorit
ID19198A (id) Inhibitor metaloprotease heterosiklik
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
ID18416A (id) Inhibitor metaloprotease diheterosiklik
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
ID18141A (id) Inhibitor metaloprotease 1,3-diheterosiklik
LV12150A (lv) Farneziltransferazes inhibitori
ID18995A (id) Amida-amida inhibitor apo b-sekresi/mtp
ATE268781T1 (de) Thrombininhibitoren
NO20003256L (no) ACE inhibitor-MMP inhibitor kombinasjoner
ID18417A (id) Inhibitor ditentat metaloprotease
FI971156A0 (fi) 5alfa-reduktaasi-inhibiittoreita
DE69733263D1 (de) Markierte elastase-inhibitoren
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
ATE282629T1 (de) Thrombininhibitoren
DE69720957T2 (de) Ace-hemmer
PT948483E (pt) Inibidores da farnesil-transferase
BR9610514A (pt) Inibidores cicloantihelmínticos
CY2007006I2 (el) Αναστολεις συνθεσεις απολιποπρωτεϊνης-β